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ARTICLE
A Chromosome 11q Quantitative-Trait Locus Influences Change
of Blood-Pressure Measurements over Time in Mexican Americans
of the San Antonio Family Heart Study
Sue Rutherford,* Guowen Cai,* Juan C. Lopez-Alvarenga, Jack W. Kent Jr., V. Saroja Voruganti,
J. Michael Proffitt, Joanne E. Curran, Mathew P. Johnson, Thomas D. Dyer, Jeremy B. Jowett,
Raul A. Bastarrachea, Larry D. Atwood, Harald H. H. Go¨ring, Jean W. MacCluer, Eric K. Moses,
John Blangero, Anthony G. Comuzzie, and Shelley A. Cole
Although previous genome scans have searched for quantitative-trait loci (QTLs) influencing variation in blood pressure
(BP), few have investigated the rate of change in BP over time as a phenotype. Here, we compare results from genomewide
scans to localize QTLs for systolic, diastolic, and mean arterial BPs (SBP, DBP, and MBP, respectively) and for rates of
change in systolic, diastolic, and mean arterial BPs (rSBP, rDBP, and rMBP, respectively), with use of the longitudinal data
collected about Mexican Americans of the San Antonio Family Heart Study (SAFHS). Significant evidence of linkage was
found for rSBP (LOD 4.15) and for rMBP (LOD 3.94) near marker D11S4464 located on chromosome 11q24.1. This same
chromosome 11q region also shows suggestive linkage to SBP (LOD 2.23) and MBP (LOD 2.37) measurements collected
during the second clinic visit. Suggestive evidence of linkage to chromosome 5 was also found for rMBP, to chromosome
16 for rSBP, and to chromosomes 1, 5, 6, 7, and 21 for the single-time-point BP traits collected at the first two SAFHS
clinic visits. We also present results from fine mapping the chromosome 11 QTL with use of SNP-association analysis
within candidate genes identified from a bioinformatic search of the region and from whole-genome transcriptional
expression data collected from 1,240 SAFHS participants. Our results show that the use of longitudinal BP data to calculate
the rate of change in BP over time provides more information than do the single-time measurements, since they reveal
physiological trends in the subjects that a single-time measurement could never capture. Further investigation of this
region is necessary for the identification of the genetic variation responsible for QTLs influencing the rate of change in
BP.
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Hypertension is a leading cause of death and morbidity
in our society,1 because it leads to stroke, heart and renal
failure, and death due to cardiovascular disease (CVD).2–7
Blood-pressure (BP) variation is influenced by both genetic
and environmental factors.8,9 Previous studies show that
BP increases with age at different rates.10,11 The rise in sys-
tolic (SBP) and diastolic (DBP) BPs is likely due to increased
peripheral resistance.12 Mean arterial BP (MBP) is highly
correlated with SBP and DBP and often describes the over-
all variation in BP.13 Data from studies suggest that MBP
is a stronger indicator of CVD risk than is pulse pressure14
or SBP,13 particularly when individual BP parameters in
adults aged !60 years are considered.
Longitudinal studies are efficient designs for the investi-
gation of individual changes, such as health and BP status,
over time.15 Longitudinal twin and family studies dem-
onstrate a substantial genetic contribution to the change
in BP over time.16,17 The concept of “variable genes,” whose
expression depends on environmental exposure, is pro-
posed to explain the longitudinal trends in BP within each
person.18,19 Genetic and epidemiological BP studies show
that use of serial measurements of BP in study participants
at multiple time points reduces measurement error and
minimizes short-term effects, because single BP measure-
ments are subject to variation from time to time within
the same individual.17,19–23 In addition, detection of link-
age may be enhanced by using longitudinal BP pheno-
types as a quantitative trait, because genes that affect BP
can contribute not only to elevated BP but also to inter-
mediate and low BPs.21 Therefore, the identification of BP-
susceptibility loci may be enhanced by analyzing mea-
surements of both long-term levels and trends in BP.
Furthermore, it has been proposed that there is a need to
investigate genetic loci for both levels and rate of change
in BP over time.17
Although many genomewide scans have been conducted
on BP phenotypes, few have investigated rate of change
in BP traits, possibly because of limited availability of lon-
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Table 1. Characteristics of the Study Sample
Sex and Characteristic Visit 1a Visit 2b
Yearly
Changeb
Men:
No. of subjects 284 255 255
Age, in years 35.5 (.92) 39.0 (.93) 5.0 (.09)
SBP 121.2 (.86) 123.4 (.94) .7 (.19)c
DBP 75.4 (.57) 72.6 (.64) .1 (.17)
MBP 88.6 (.58) 89.5 (.67) .2 (.16)
BMId 28.6 (.35) 29.5 (.38) .2 (.04)c
Waist circumference, in mm 963.0 (10.25) 998.2 (9.30) 10.0 (1.14)c
Triglycerides 1.76 (.08) 1.63 (.09) .00 (.02)
Total cholesterol 4.86 (.06) 4.62 (.06) .04 (.01)c
HDL cholesterol 1.26 (.02) 1.22 (.02) .01 (.00)
Women:
No. of subjects 455 406 406
Age, in years 36.5 (.68) 39.8 (.70) 5.2 (.07)
SBP 115.4 (.80) 118.9 (.85) 1.1 (.12)c
DBP 68.8 (.46) 70.1 (.50) .3 (.11)
MBP 84.3 (.51) 86.3 (.56) .6 (.10)c
BMId 29.7 (.34) 30.5 (.36) .2 (.04)c
Waist circumference, in mm 919.1 (8.30) 975.3 (8.54) 14.0 (1.26)c
Triglycerides 1.49 (.05) 1.46 (.06) .01 (.01)
Total cholesterol 4.83 (.04) 4.53 (.04) .05 (.01)
HDL cholesterol 1.36 (.02) 1.28 (.02) .02 (.00)
NOTE.—All values are mean (SE). BP is measured in mm Hg. Cholesterol is mea-
sured in mmol/liter.
a Excludes individuals who reported treatment with antihypertensive medication
at visit 1; lipid estimates also exclude individuals ( ) who reported treatmentnp 7
with antihyperlipidemia medication at visit 1.
b Excludes individuals who reported treatment with antihypertensive medication
at either visit; lipid estimates also exclude individuals ( ) who reported treatmentnp 18
with antihyperlipidemia medication at either visit.
c Significantly different from 0 at (one-tailed t test, withP ! .003125 ap .05
Bonferroni correction for eight tests per sex).
d Calculated as weight in kilograms divided by the square of height in meters.
gitudinal data and limitations in analytical methods.24
Even fewer studies have investigated MBP over time as a
trait for genomewide scans. We decided to compare results
from a genomewide scan that used the rates of change in
SBP (rSBP), DBP (rDBP), and MBP (rMBP) (calculated as
the difference between two measures in two clinic visits
divided by the time interval between visits) with results
from a genomewide scan that used the single-time-point
BP measurements collected from Mexican American par-
ticipants of the San Antonio Family Heart Study (SAFHS).
In addition, we show results from a novel exploratory fine-
mapping approach that makes use of a combination of
gene-expression data, bioinformatics, and SNP-association
analyses in this Mexican American population.
Subjects and Methods
SAFHS Population
The subjects in this study were Mexican American participants
of the SAFHS.25 Probands and their relatives were invited to the
clinic once during 1990–1992 (first clinic visit), again during 1994–
1996 (second clinic visit), and for a third time during 2004–2006.
Over 1,400 subjects from 42 large, extended families were re-
cruited in clinic visit 1. Families were recruited, without regard
to disease status, around an index case (proband) who was Mex-
ican American and aged 40–60 years. To assure large families,
probands were required to have a spouse and at least six age-
eligible offspring and/or siblings living in San Antonio. Infor-
mation about medical history, family relationship, lifestyle, and
anthropometry were obtained, and blood samples were drawn
from the participants. BPs were measured three times on the left
arm by a random-zero sphygmomanometer, and the averages of
the latter two measures were used as trait values. MBP was cal-
culated using the formula .MBPp 1/3(SBP) 2/3(DBP)
Of the 817 subjects with BP data collected on the first and
second clinic visits, we used data from 739 of these subjects for
the first-clinic-visit BP genome scan after excluding individuals
who reported treatment with antihypertensive medication at that
visit. We used 661 of these subjects for the longitudinal and the
second-clinic-visit BP genomewide scans after excluding individ-
uals who reported treatment with antihypertensive medication
at either clinic visit.
Body weight, height, and waist and hip circumferences were
recorded according to standard protocol,26 and lipid panels were
measured with a Ciba-Corning Express Plus clinical chemistry
analyzer with commercial reagents (Roche Diagnostics and Stan-
bio). The high-density lipoprotein (HDL) cholesterol was quan-
tified in plasma samples after precipitation of b lipoproteins with
dextran sulfate.27 All protocols in this study were approved by
the Institutional Review Board of the University of Texas Health
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Figure 1. Multipoint linkage analysis of rate of change in BP traits, with use of a 10-cM genome scan of Mexican Americans of the
SAFHS. Traits analyzed are rSBP (black), rDBP (blue), and rMBP (red). The horizontal scale shows LOD scores 11.5, and the vertical scale
shows distance (cM).
Science Center at San Antonio, and all participants gave informed
written consent.
Genomewide Screening
Lymphocytes were isolated from whole blood, and DNA was ex-
tracted for genotyping. For the genomewide scan, genomic DNA
was amplified by PCR with use of 432 fluorescently labeled prim-
ers from MapPairs 6 and 8 Linkage Screening Sets (Research Ge-
netics). The PCR products were pooled and analyzed using an
automated DNA sequencer (Applied Biosystems [ABI] model 377,
with Genescan and Genotyper programs).
Multipoint linkage analyses were conducted using the variance-
decomposition method implemented in SOLAR (Hlod).28,29 The
variance-components linkage method is based on classic quan-
titative genetic principles, in which the phenotype is assumed to
be influenced by both genetic and environmental factors. The
genetic factors can include effects of shared alleles at specific loci
at defined chromosomal locations. Evidence of genetic effects is
obtained from the observed covariances among different classes
of relatives.
The observed phenotypic covariances among individuals are
decomposed into partial covariances on the basis of allele sharing
at specific loci (on the basis of marker genotypes), allele sharing
elsewhere in the genome (on the basis of kinship), and nonad-
ditive genetic factors. If the variance component for a specific
chromosomal location is significantly greater than zero, there is
evidence of a locus influencing the phenotype at that location.
In practice, we tested for the existence of a locus influencing the
phenotype at intervals across the entire autosomal genome.
Parameter estimation and hypothesis testing are performed us-
ing a maximum-likelihood framework, under the assumption of
multivariate normality. For each BP trait, we test the null hypoth-
esis that the additive genetic variance due to a specific QTL equals
zero (no linkage) by comparing the likelihood of this restricted
model with that of a model in which the variance due to this
QTL is estimated.
The difference between the two log10 likelihoods yields a LOD
score, which measures the support for the hypothesis of linkage
over that of “no linkage” at a given chromosomal location. A
LOD score of 3.0, for example, indicates that the statistical sup-
port for the linkage hypothesis is 103 times that for the null hy-
pothesis. Since this represents a pointwise corrected forP ! .05
the multiple tests in a typical genome scan, LOD 3 is custom-
arily taken as significant evidence of linkage.30 P values for this
test are obtained from twice the difference in loge likelihoods of
these two models, which yields a test statistic that is asymptot-
ically distributed as a mixture of a x2 variable and a(1/2):(1/2)
point mass at zero.31
Data for the longitudinal BP study were transformed either by
natural-logarithm transformation or inverse-normalization pro-
cedures (rSBP, rDBP, and rMBP), to reduce skewness and kurtosis
(leptokurtic distributions may increase the type 1 error rate in
multipoint analyses).32 The inverse normal transformation of a
data set is performed by the following procedure. First, the trait
values are sorted, and, for any value V found at position I in the
sorted list, a quantile is computed for it by the formula I/(N
. The inverse-normal-cumulative-density function is computed1)
for each quantile and is stored in an array keyed by ID and by
family ID, if applicable. When the value V occurs multiple times,
the inverse normal is computed for each applicable quantile and
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Table 2. Genome-Scan Results with LOD
Scores 1.9
Traita and
Chromosome
Locationb
(cM) Nearest Marker LOD
rMBP:
5 31 D5S817 2.0
11 132 D11S4464 3.94
rSBP:
11 132 D11S4464 4.15
16 52 D16S769 2.73
rDBP:
11 133 D11S4464 2.27
MBP2:
1 203 D1S1660–D1S1668 2.34
5 192 D5S1456–D5S211 1.94
11 105 D11S2000 2.37
11 117 D11S1998 2.17
SBP2:
1 193 D1S1660–D1S1668 2.08
5 187 D5S1456–D5S211 2.53
7 165 D7S1805 2.06
11 117 D11S1998 2.23
DBP2:
5 192 D5S1456–D5S211 1.97
11 101 D11S2000 2.63
MBP1:
21 21 D21S1437 2.44
SBP1:
6 83 D6S1053 2.15
a Traits analyzed: rSBP, rDBP, and rMBP; SBP (SBP2),
DBP (DBP2), and MBP (MBP2) from clinic visit 2; and
SBP (SBP1), DBP (DBP1), and MBP (MBP1) from clinic
visit 1.
b Locations are based on the deCODE map.
Figure 2. Multipoint linkage analysis of rate of change in BP
traits, with use of a 10-cM genome scan of chromosome 11 in
Mexican Americans of the SAFHS. Tick marks indicate marker
locations.
is averaged, and then the average is stored for each ID. We in-
corporated sex, age at visit 1, and the inverse-normal-transformed
rate of change in BMI (rBMI) as covariates into the longitudinal
analysis.
For the single-time-point BP-measurement genome scan, we
used inverse-normal-transformed data for SBP, DBP, and MBP at
each clinic visit and incorporated sex, age at that visit (1 or 2),
and inverse-normal-transformed BMI at that visit (1 or 2) as co-
variates in the analysis.
We also tested for locus heterogeneity when significant evi-
dence of linkage was obtained for a particular locus. We used the
heterogeneity LOD (HLOD) routine in SOLAR to perform a classic
heterogeneity test under a model allowing for two sets of families,
with only one set segregating the locus of interest. The distribu-
tion of the test statistic for homogeneity conditional on linkage
is taken to be a 50:50 mixture of a x2 distribution with 1 df and
a point mass at zero (HLOD).
Gene-Expression Analysis
RNA was extracted from lymphocytes isolated from whole blood
available from 1,280 SAFHS participants. The gene-expression data
presented here were acquired as part of the whole-genome gene-
expression analysis in the SAFHS (H.H.H.G., J.E.C., M.P.J., T.D.D.,
S.A.C., J.B.J., D. L. Rainwater, A.G.C., M. C. Mahaney, L. Almasy,
J.W.M., G. R. Collier, E.K.M., and J.B., unpublished data). In sum-
mary, expression levels of 47,289 different transcripts from 1,280
members of 42 SAFHS Mexican American families were tested
using Illumina’s Sentrix Human-6 gene-expression bead chips (v.
1). We identified 20,413 transcripts that exhibited significant ex-
pression in 1,240 SAFHS subjects. Genomewide variance com-
ponents–based linkage analysis was performed on the expression
levels of all transcripts (H.H.H.G., J.E.C., M.P.J., T.D.D., S.A.C.,
J.B.J., D. L. Rainwater, A.G.C., M. C. Mahaney, L. Almasy, J.W.M.,
G. R. Collier, E.K.M., and J.B., unpublished data). Heritability es-
timates were also obtained for each transcript (H.H.H.G., J.E.C.,
M.P.J., T.D.D., S.A.C., J.B.J., D. L. Rainwater, A.G.C., M. C. Ma-
haney, L. Almasy, J.W.M., G. R. Collier, E.K.M., and J.B., unpub-
lished data). For the present study, regression analyses were per-
formed to estimate the mean effect of transcripts from genes
within the chromosome 11 linkage region. For each BP pheno-
type, each transcript was tested separately as a covariate in the
peak linkage model, to estimate both the significance of the re-
gression (as probability that the regression ) and theslopep 0
change in the QTL-specific variance (conditional linkage).33
Bioinformatic Analysis
We used the computer software GeneSniffer to investigate the
potential relevance of each gene in our region to BP.34 GeneSniffer
identifies all known and predicted genes within a defined chro-
mosome region by mining bioinformatics databases from the
National Center for Biotechnology Information Entrez Gene,
OMIM, and PubMed, to objectively identify plausible positional
candidate genes. Interrogation of these databases is performed
using a set of disease-specific keywords that are assigned a score
(scale 1–10, with 10 as the greatest) on the basis of their relevance
and significance to a particular phenotype of interest.34 Gene-
Sniffer also performs analysis to identify genes homologous to
those in the region of interest. Homologues of each gene within
the region of interest are identified by BLAST and are scored for
content in their Entrez Gene, OMIM, and PubMed entries. Each
score is weighted in accordance with the degree of homology,
and a cumulative “hit score” is calculated for each gene. Scores
generated for both the relevance to keywords and to homology
of other genes are documented in an HTML format for all genes
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Figure 3. Multipoint linkage analysis of BP traits from clinic visit 1, with use of a 10-cM genome scan of Mexican Americans of the
SAFHS. Traits analyzed are SBP (black), DBP (blue), and MBP (red) collected at clinic visit 1. The horizontal scale shows LOD scores
11.5, and the vertical scale shows distance (cM).
within the region of interest. Also listed in the HTML format are
the source of database hits and links to external databases for
additional information. GeneSniffer therefore provides a quan-
titative indicator of the relevance of a gene to a particular phe-
notype of interest.
SNP Analysis
SNPs located in coding and regulatory regions of genes were pref-
erentially selected for genotyping and analysis. Special priority
was given to SNPs that predict functional changes in these
genes—for example, missense, nonsense, and splice-site muta-
tions. SNPs that were experimentally validated by HapMap or by
Applera Genome Resequencing Initiative were chosen for further
evaluation. For this reason, primers and probes for TaqMan allelic
discrimination assays of 85 validated SNPs were purchased either
from the ABI Predesigned or Validated and Coding SNP Geno-
typing Assays. TaqMan reactions contained 10 ng genomic DNA
in a 5-ml reaction volume containing 1x TaqMan Universal PCR
Master Mix without AmpErase uracil-N-glycosylase (2x), the PCR
primers, and both the FAM and VIC reporter-labeled TaqMan
MGB probes for the SNP at 1x final concentration. The amplifi-
cation conditions consisted of an initial incubation step at 95C
for 10 min, followed by 40 cycles at 92C for 15 s and then at
60C for 1 min, with use of an ABI Prism 7900 sequence-detection
system.
An allelic-transmission scoring method (the QTL disequilib-
rium test [QTLD]) incorporated into SOLAR Hlod35 was used to
test the 85 SNPs for association with each BP phenotype. We
tested for population stratification for each SNP by comparing
the likelihood of a model in which the association parameters
are estimated separately for each pedigree with one in which they
are constrained to be equal, as would be expected in the absence
of population stratification. In the presence of population strati-
fication, we conducted a quantitative transmission/disequilibrium
test (QTDT)36 incorporated into QTLD for this contingency.35 Age
and sex were incorporated into all analyses as covariates.
Results
Genomewide Scan of Single-Time-Point and Longitudinal BP
Traits
Table 1 shows the characteristics of the male and female
subjects used in this study at both clinic visits. Since the
studied population was getting older during the 3–4 years
between visits 1 and 2, positive average yearly changes
of BMI, waist circumference, triglycerides, SBP, and MBP
were observed in both males and females. Negative av-
erage yearly changes were seen in measurements of HDL
and total cholesterol levels in both sexes. Changes in BMI,
waist circumference, SBP, and MBP in females and in BMI,
waist circumference, total cholesterol, and SBP in males
were significantly different from zero (table 1). We ob-
served minor differences in DBP in both sexes, but these
changes were not significant (table 1). It is important to
note that the mean differences in table 1 are not adjusted
for age or BMI, as are the phenotypes in the genetic anal-
yses, and do not take into account the kinship between
the subjects. Thus, table 1, although not a formal epide-
miological comparison (because the subjects are related
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Figure 4. Multipoint linkage analysis of BP traits from clinic visit 2, with use of a 10-cM genome scan of Mexican Americans of the
SAFHS. Traits analyzed are SBP (black), DBP (blue), and MBP (red) collected at clinic visit 2. The horizontal scale shows LOD scores
11.5, and the vertical scale shows distance (cM).
and are thus not independent), is suggestive of overall
trends in the study sample.
The longitudinal BP genome-scan results are shown in
figure 1. We found evidence of linkage that met the criteria
for genomewide significance on chromosome 11q24.1 for
rSBP (LOD 4.15; ) and for rMBP (LOD 3.94;Pp .000006
) near marker D11S4464 (table 2 and fig. 2).Pp .00001
The same marker also was linked to rDBP (LOD 2.27;
) (table 2 and fig. 2). We identified suggestivePp .0006
linkage of rSBP to the D16S769 marker on chromosome
16 (LOD 2.73; ) and of rMBP to the D5S817Pp .0002
marker on chromosome 5 (LOD 2.0; ) (table 2).Pp .001
Since we excluded those being treated with antihyperten-
sive medication, we reanalyzed the chromosome 11q lon-
gitudinal data for all 817 individuals, including those who
were being treated with antihypertensive medication at
visit 1 or 2. We incorporated the treatment with antihyper-
tensive medication as well as sex, age at visit 1, and the
inverse-normal-transformed rBMI as covariates in the link-
age analysis. Results show that including those with ex-
treme pathology and incorporating treatment with anti-
hypertensive medication as a covariate in the analysis ac-
tually improved the linkage signal for rMBP (LOD 4.8;
) and for rDBP (LOD 3.2; ), where-Pp .000001 Pp .00006
as rSBP remained the same (LOD 4.15; ). WePp .000006
also reanalyzed the rSBP linkage result with just sex and
age as covariates. The results show that the rate of change
in BMI as a covariate in the analysis (rSBP LOD 4.15 with
rBMI as a covariate) actually improves our linkage signal
for rSBP (LOD 3.97 without rBMI as a covariate). Since we
obtained significant evidence of linkage to chromosome
11, we tested for locus heterogeneity at this locus by con-
ducting a multipoint HLOD analysis for rSBP. HLOD re-
sults for rSBP were negative for locus heterogeneity, mean-
ing that all of the pedigrees contributing to the QTL in
this region show a high probability of linkage.
We adjusted the linkage evidence (LOD score) on chro-
mosome 11q downward by comparison with the empirical
distribution of LOD scores in the absence of linkage (using
the “LOD adjust” routine in SOLAR (Hlod) with at least
10,500 replicates per trait).32 We maintained our evidence
of linkage to this chromosome 11q24.1 region with an
adjusted LOD of 3.96 ( ) for rSBP and4.15# 0.955p 3.96
an adjusted LOD of 3.35 ( ) for rMBP.3.94# 0.85p 3.35
The single-time-point BP genome-scan results are shown
in figure 3 for clinic visit 1 and in figure 4 for clinic visit
2. We found suggestive evidence of linkage of MBP col-
lected at clinic visit 2 (MBP2) near D11S2000 (LOD 2.37;
) and D11S1998 (LOD 2.17; ), whichPp .0005 Pp .0008
is positioned 5.9 Mb from D11S4464 and within the 16-
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Table 3. Gene-Expression Results for rSBP and rMBP in Chromosome 11q QTLs
BP Change
and Gene
Symbol h2 (P)
Reduction in
LOD Score
(%)
Regression
Coefficient
(b)
GeneSniffer
Ranka
No. of SNPs
Tested
rSBP:
CHEK1 .17 (5#105) 13.8 .073 1 3
EI24 .25 (2#108) 5.7 .078 NA 0
PHLDB1 .19 (4# 107) 4.9 .041 NA 1
rMBP:
EI24 .25 (2#108) 9.0 .059 NA 0
CHEK1 .17 (5#105) 5.8 .016 1 3
TMEM25 .20 (2#107) 5.2 .037 NA 0
RPUSD4 .18 (1#106) 4.8 .10 NA 0
a Of 221 genes. NA p not applicable.
Mb 1-LOD–score support interval surrounding the rSBP
and rMBP QTLs. We also found suggestive linkage of DBP
in visit 2 (DBP2) near D11S2000 (LOD 2.63; ) andPp .003
of SBP in visit 2 (SBP2) near D11S1998 (LOD 2.23; Pp
). Suggestive evidence of linkage was also found on.0007
chromosome 5 for MBP2, SBP2, and DBP2; on chromo-
some 1 for MBP2 and SBP2; on chromosome 7 for SBP2;
on chromosome 6 for SBP at clinic visit 1 (SBP1); and on
chromosome 21 for MBP at clinic visit 1 (MBP1), as out-
lined in table 2.
Gene-Expression Analysis
We analyzed the lymphocyte transcript–expression levels
whose coding loci are within the 1-LOD–score support
interval on chromosome 11 (∼16 Mb physical distance),
to determine the extent to which the transcripts account
for the original linkage for rSBP and rMBP. We quantified
the expression of a total of 169 transcripts representing
157 (71%) of the 221 genes in our 1-LOD–score support
interval. The genes with the highest percentage LOD-score
reduction for rSBP and rMBP are shown in table 3. Raw
and processed transcript information for the five genes
listed in table 3 is available in a txt file (online only), which
can be imported into a Microsoft Excel spreadsheet. The
expression levels of all genes listed in table 3 are signifi-
cantly heritable ( ). The transcript exerting theP ! .00001
largest effect (13.8%) in reducing the rSBP LOD score was
CHEK1 (MIM 603078), whereas EI24 (MIM 605170) had
the largest reduction (9.0%) in the rMBP LOD score (table
3).
Expression levels for CHEK1 and EI24 were also the sec-
ond-most influential transcripts in reducing the LOD scores
for rMBP (5.8%) and rSBP (5.7%), respectively (table 3).
CHEK1 was positively correlated with rSBP ( )bp 0.073
and rMBP ( ), whereas EI24 was negatively cor-bp 0.016
related with rSBP ( ) and rMBP ( 0.059)bp0.078 bp
in our Mexican American families. Of the remaining genes
listed in table 3, PHLDB1 reduced the rSBP LOD score by
4.9%, whereas TMEM25 and RPUSD4 reduced the rMBP
LOD score by 5.2% and 4.8%, respectively (table 3).
PHLDB1 was positively correlated with rSBP ( ),bp 0.041
whereas TMEM25 and RPUSD4 were positively correlated
with rMBP ( and , respectively) in ourbp 0.037 bp 0.10
Mexican American families.
Bioinformatic Analysis
We used GeneSniffer to rank the most likely candidate
genes in our 16-Mb chromosome 11q region, as shown in
tables 3 and 4. Although CHEK1 has no known involve-
ment in BP regulation, CHEK1 was identified by Gene-
Sniffer to be the strongest candidate in this region, because
it has similarity to the serine/threonine kinase family
(Swiss-Prot). CHEK1 therefore belongs to the Ser/Thr pro-
tein kinase family NIM1 subfamily (Swiss-Prot). Two mem-
bers of the serine/threonine kinase family—WNK1 (MIM
605232) and WNK4 (MIM 601844)—were identified in a
rare monogenic hypertension syndrome known as “Gor-
don syndrome,” or psuedohypoaldosteronism type 2
(PHA2 [MIM 145260]).37,38 These WNK genes belong to the
Ser/Thr protein kinase family WNK subfamily (Swiss-Prot).
Both the CHEK1 and WNK genes have a conserved region
containing the protein kinase domain. There is ∼27% ho-
mology between the CHEK1 and WNK proteins within
this conserved region.
SNP-Association Analysis
We selected a total of 85 SNPs reported elsewhere from 49
genes identified as potential BP candidates. We selected
three SNPs in CHEK1, because GeneSniffer ranked it as the
strongest candidate gene and its expression level reduced
the rSBP and rMBP LOD score by 13.8% and 5.8%, respec-
tively (table 3). We also selected a SNP in PHLDB1, because
the expression level of this transcript reduced the rSBP
LOD score by 4.9% (table 3). In addition, we selected 18
SNPs within 15 genes that we considered likely BP can-
didate genes that did not have enough information to be
ranked by GeneSniffer. The remaining 63 SNPs were po-
sitioned in 31 genes that were within the top third of
most-likely BP candidates identified by our bioinformatic
searching (table 4). The 85 SNPs were genotyped in all
1,400 Mexican American participants in the SAFHS.
Association analysis shows that SNPs in nine genes had
marginal association ( ) with rDBP, rSBP, or rMBPP ! .048
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Table 4. SNPs Selected in the Potential BP Candidate Genes Positioned
within Our 1-LOD–Score Support Interval on Chromosome 11q
Location
(Mb)
Gene
Symbol
Size
(kb)
GeneSniffer
Rankinga
No. of SNPs P
Coding Tested rMBP rDBP rSBP
111.520 IL18 20.9 NA 0 1 NS NS NS
112.370 NCAM1 315.2 4 0 1 NS NS NS
112.786 DRD2 65.6 3 0 1 NS NS NS
113.281 HTR3B 41.7 43 1 1 NS NS NS
113.351 HTR3A 15.1 23 1 1 NS NS NS
116.206 APOC3 3.2 19 1 1 NS NS NS
116.212 APOA1 1.9 2 0 3 NS NS NS
116.609 RNF214 52.6 NA 0 2 NS NS NS
116.804 DSCAML1 369.5 52 1 3 NS NS NS
117.363 IL10RA 15.1 62 1 4 NS NS NS
117.453 TMPRSS4 41.4 64 1 2 .047 NS NS
117.509 SCN4B 19.4 30 0 1 NS NS NS
117.681 EVA1 10.9 24 1 2 NS NS NS
117.736 UBE4A 39.6 NA 0 2 .037 NS NS
117.812 MLL 85.7 NA 1 1 .048 NS NS
117.982 PHLDB1 51.5 NA 1 1 NS .019 NS
118.126 DDX6 41.5 NA 1 1 NS NS NS
118.400 SLC37A4 6.4 NA 0 1 NS NS NS
118.472 DPAGT1 5.6 NA 1 1 NS NS NS
118.525 ABCG4 13.6 NA 0 1 NS NS NS
118.684 MCAM 8.9 13 1 1 NS NS NS
118.715 C1QTNF5 1.9 25 1 1 NS NS NS
118.794 THY1 5.0 14 1 1 NS NS .019
119.616 POU2F3 79.6 42 1 3 .033 .023 NS
119.782 ARHGEF12 83.8 41 0 3 NS NS NS
120.36 GRIK4 325.9 27 0 6 .018 .029 NS
120.479 TECTA 88.1 26 1 1 NS NS NS
120.828 SORL1 177.5 31 1 3 NS NS NS
121.491 BRCC2 .9 NA 0 1 NS NS NS
122.032 STS-1 156.7 8 0 2 NS NS NS
122.393 HSPA8 4.6 10 0 1 NS .009 NS
122.448 ASAM 123.0 47 0 3 NS NS NS
123.007 SCN3B 7.0 33 0 1 NS NS NS
123.100 ZNF202 7.0 NA 1 1 NS NS NS
123.491 LOH11CR2A 31.5 NA 1 1 NS NS NS
123.998 TBRG1 11.5 56 0 3 NS NS NS
124.010 SIAE 38.0 NA 0 1 NS NS NS
124.128 ESAM 9.1 35 1 1 NS NS NS
124.240 ROBO3 16.5 28 1 3 NS NS .046
124.438 SLC37A2 25.9 NA 1 1 NS NS NS
124.821 FEZ1 50.5 49 0 1 NS NS NS
125.002 CHEK1 29.3 1 0 3 NS NS NS
125.336 CDON 102.6 50 1 1 NS NS NS
125.638 SRPR 5.9 NA 1 1 NS NS NS
125.679 DCPS 42.0 NA 1 2 NS NS NS
125.731 ST3GAL4 58.4 61 1 1 NS NS NS
125.800 KIRREL3 575.9 78 0 2 NS NS NS
128.069 FLI1 118.3 11 2 4 NS NS NS
128.213 KCNJ1 29.4 5 0 1 NS NS NS
Total 28 85
NOTE.—Shown is the GeneSniffer ranking of each selected gene and the results from SNP-
association analysis. NS p .P 1 .05
a Of 221 genes. NA p not applicable.
(table 4). Table 5 also lists the mean values by genotype
for rDBP, rSBP, and rMBP for the nine significant SNPs.
Although the reported P values are nominal and are not
adjusted for the multiple tests conducted, our most prom-
ising result was found between rDBP and rs7111598 (Pp
), located 2,055 bp from the 3′ UTR for the heat shock.009
protein 8 gene (HSPA8 [MIM 600816]). Interestingly, Gene-
Sniffer ranked this gene as the 10th-most likely BP can-
didate in this region (table 4). Although we tested only
three intronic SNPs, we did not detect any association
between the rates of change in any BP traits with the
CHEK1 gene that GeneSniffer ranked as the most likely
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Table 5. Mean Values by Genotype for rSBP, rDBP, and
rMBP
Trait and SNP
Chromosome
11 Position
(Mb)
Mean Value (SE) by Genotype
AA AB BB
rSBP:
rs3741311 117.49 .686 (.24) .892 (.20) 1.096 (.28)
rs6589663 117.76 1.050 (.20) .590 (.23) .132 (.39)
rs629470 117.83 .889 (.21) .624 (.30) .358 (.54)
rs498872 117.98 .864 (.21) .789 (.21) .716 (.34)
rs1001205 118.80 .799 (.25) .834 (.20) .868 (.28)
rs2282537 119.69 .963 (.14) 1.426 (.27) 1.890 (.52)
rs10790400 120.06 1.116 (.24) .864 (.19) .613 (.25)
rs7111598 122.43 .875 (.20) .735 (.24) .595 (.40)
rs7925879 124.25 1.113 (.19) 1.036 (.14) .959 (.23)
rDBP:
rs3741311 117.49 .160 (.20) .002 (.15) .163 (.17)
rs6589663 117.76 .132 (.15) .097 (.17) .327 (.29)
rs629470 117.83 .019 (.15) .173 (.22) .366 (.39)
rs498872 117.98 .177 (.16) .087 (.16) .350 (.25)
rs1001205 118.80 .130 (.18) .109 (.14) .348 (.21)
rs2282537 119.69 .042 (.11) .648 (.20) 1.253 (.39)
rs10790400 120.06 .124 (.18) .050 (.14) .024 (.19)
rs7111598 122.43 .145 (.15) .200 (.18) .544 (.30)
rs7925879 124.25 .288 (.14) .126 (.10) .035 (.17)
rMBP:
rs3741311 117.49 .104 (.17) .317 (.14) .529 (.20)
rs6589663 117.76 .445 (.14) .149 (.17) .148 (.28)
rs629470 117.83 .322 (.15) .072 (.22) .178 (.39)
rs498872 117.98 .396 (.16) .238 (.15) .078 (.25)
rs1001205 118.80 .306 (.18) .227 (.14) .147 (.21)
rs2282537 119.69 .372 (.11) .924 (.19) 1.475 (.38)
rs10790400 120.06 .429 (.18) .337 (.14) .244 (.19)
rs7111598 122.43 .377 (.15) .156 (.18) .065 (.30)
rs7925879 124.25 .571 (.14) .441 (.10) .311 (.17)
candidate gene in the region. We observed significant asso-
ciation between rDBP and rs498872 ( ), positionedPp .019
within the 5′ UTR of PHLDB1; rs2282537 ( ), posi-Pp .023
tioned within exon 12 of POU2F3 (MIM 607394); and
rs10790400 ( ), positioned within intron 1 of GRIK4Pp .029
(MIM 600282). A bioinformatic search of these genes with
use of GeneSniffer ranked GRIK4 and POU2F3 as the 27th-
and 42nd-most likely BP candidate genes in this region
(table 4). There was not enough available information for
GeneSniffer to rank PHLDB1. Interestingly, rs10790400,
positioned within intron 1 of GRIK4, and rs2282537, a
missense mutation (Lys390Arg) positioned within exon 12
of POU2F3, also showed significant association to rMBP
( and , respectively). Significant associ-Pp .018 Pp .033
ation was also found between rMBP and rs6589663 (Pp
), positioned within intron 13 of UBE4A (MIM.037
603753); rs3741311 ( ), positioned within the 3′Pp .047
UTR of TMPRSS4 (MIM 606565); and rs629470 ( ),Pp .048
positioned within intron 1 of MLL (MIM 159555). Gene-
Sniffer did not rank UBE4A and MLL but ranked TMPRSS4
as the 64th-most likely BP candidate in the region (table
4). Only two SNPs—rs1001205, positioned within intron
1 of THY1 (MIM 188230), and rs7925879, positioned
within intron 6 of ROBO3 (MIM 608630)—showed nom-
inal significant association to rSBP ( andPp .019 Pp
, respectively). GeneSniffer respectively ranked THY1.046
and ROBO3 as the 14th- and the 28th-most likely BP can-
didate genes in this region (table 4).
Discussion
The key finding in this study is the identification of
QTLs for longitudinal BP measurements on chromosome
11q near marker D11S4464. Five other studies also report
modest evidence of linkage to BP and/or hypertension on
chromosome 11q, consistent with our results. The pop-
ulations include: U.K. whites,39 U.S. whites,40 African
Americans from the Hypertension Genetic Epidemiology
Network (HyperGen),41 Hong Kong Chinese,42 and whites
from the Health, Risk Factors, Exercise Training and Ge-
netics (HERITAGE) study.43 The U.K. population study
identified a 44-cM linkage region with peak linkage oc-
curring near marker D11S934 ( ) in 169 sib pairsP ! .004
affected with early-onset (aged !50 years) hypertension.39
Their peak linkage occurred within 3 Mb of our own link-
age peak in Mexican Americans. This is also within 24 Mb
of a QTL in the HyperGen study, which found a LOD score
of 1.23 ( ) on chromosome 11q in 169 AfricanPp .0087
American sibships with two or more individuals with hy-
pertension onset before age 35 years.41 Another study of
early-onset hypertension in U.S. whites also identified
peak linkage (LOD 1.66; ) within 50 Mb of ourPp .0029
QTL region.40 In Hong Kong Chinese, a LOD score of 1.44
( ) was found between D11S1995 and D11S1998Pp .005
for SBP.42 This linkage peak occurred within 11 Mb of our
linkage peak and within 44 Mb of a QTL in the HERITAGE
study of whites, where a LOD score of 1.98 ( )Pp .0013
near the D11S2002 marker was identified for resting SBP.43
Therefore, our linkage to the rate of change of SBP (LOD
4.15) on chromosome 11q replicates the previous findings
of linkage to SBP in Hong Kong Chinese42 and to resting
SBP identified in the HERITAGE study of whites43 in this
same chromosome 11q region.
In addition to these results, QTLs in this genomic region
have been identified elsewhere for BP-related traits. In Pima
Indians, the same marker, D11S4464, was linked to BMI
and type 2 diabetes, with LOD scores of 3.6 and 1.7, re-
spectively.44 In the Framingham study, six measures of BMI
at different times mapped to the same region.45 Percentage
of body fat and energy expenditure may also be related
to the QTL in this region.46 However, there is evidence
that this region of chromosome 11q contains genetic var-
iation affecting hypertension and/or BP independent of
obesity and insulin-resistance phenotypes. In the genetic
analyses for the HyperGen and HERITAGE studies, incor-
poration of BMI as a covariate did not significantly affect
the evidence of linkage of early-onset hypertension41 and
resting SBP43 to chromosome 11q. In addition, little of the
variation in SBP was explained by waist circumference and
insulin resistance, as measured by the HOMA-IR (i.e., ho-
meostasis model assessment of insulin resistance), when
incorporated into the linkage analysis of SBP in the Hong
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Kong Chinese study.42 Our results show that the rate of
change in BMI as a covariate in the analysis (rSBP LOD
4.15 with rBMI as a covariate) actually improves our link-
age signal for rSBP (LOD 3.97 without rBMI as a covariate),
implying that changes in weight are not responsible for
our QTLs for changes in BP over time.
We also find that the use of measurements of long-term
levels of BP provides a better insight into the identification
of BP-susceptibility loci, particularly in this chromosome
11q region. This conclusion is based on a comparison of
the longitudinal and single-time-point BP genome scans.
Significant evidence of linkage is obtained for rSBP and
rMBP near the D11S4464 marker, but only suggestive evi-
dence of linkage of SBP and MBP is found within this
region. We attribute the higher LOD scores obtained for
rate of change in BP traits to the longitudinal data that
provide more information than the single-time measure-
ments, since they reveal physiological trends in the sub-
jects that a single-time measurement could never capture,
particularly in this chromosome 11q region. This is further
supported by the lack of replication in linkage results be-
tween single-time-point BP traits from clinic visit 1 and
clinic visit 2. The results showing suggestive linkage to
clinic visit 2 BP traits, together with the significant linkage
to the rate of change in BP traits, provide further support
for a BP-susceptibility locus on chromosome 11q in Mex-
ican Americans of the SAFHS. However, further investiga-
tion of this region is necessary to identify the genetic var-
iant(s) responsible for the localization of an age-related BP
QTL within the chromosome 11q region.
For this reason, we began identifying the responsible ge-
netic variant(s) by a combination of bioinformatic search
of databases, gene expression, and preliminary explora-
tory SNP-association analyses within the 16-Mb 1-LOD–
score support interval of our chromosome 11q QTL. We
found agreement in results between the gene-expression
and GeneSniffer analyses, because both identified CHEK1
as the most promising BP-candidate gene in the chromo-
some 11q QTL region. Although testing three intronic SNPs
did not implicate CHEK1 involvement in any of the
change in BP traits, we feel that this gene is our most
promising positional candidate in our chromosome 11q
BP QTL region. Although SNP analysis identified involve-
ment for a number of other genes in this region, we found
little agreement in results among the three different meth-
ods for these additional genes. This may occur because the
initial SNP panel was too sparse to thoroughly analyze all
of the plausible candidate genes in the region. Further
investigation may find linkage disequilibrium between the
SNPs in this study and those yet to be genotyped in genes
identified by GeneSniffer and gene-expression analysis.
Some would also argue that the lack of consistency
among the three fine-mapping approaches for these addi-
tional genes occurred because gene expression in lympho-
cytes is not representative of gene expression in tissues
relevant to hypertension. Previous studies show that lym-
phocytes express a number of BP-related genes—including
angiotensin 1–converting enzyme,47 angiotensin II, and
renin48—and several receptors—including cytokines, glu-
cocorticoids, catecholamines, dopamine, and acetylcho-
line.49 Examination of gene-expression levels in lympho-
cytes may also detect other genes (such as CHEK1) that
normally are not considered to have involvement in BP
regulation. For these reasons, we believe lymphocyte-ex-
pression studies to be quite valuable for etiological studies.
We conclude that a more thorough SNP investigation
of CHEK1 may identify the responsible genetic variant(s).
This, in turn, will provide further proof that a combina-
tion of GeneSniffer, gene-expression, and SNP-association
analyses is the most effective approach for the identifi-
cation of positional candidate genes contributing to our
chromosome 11q change in BP QTLs in Mexican Ameri-
cans of the SAFHS. Genetic variation that is ultimately
identified as affecting the regulation of BP over time may
not be confined to Mexican Americans, and studies of
other populations that include a simple longitudinal re-
cording of an individual’s BP measurement along with
screening for the existence of the identified variant(s) will
confirm this phenomenon.
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